Americas was Codexis’s largest region in fiscal 2025, bringing in $43.54M of $70.39M (62%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apac | $65.05M | $33.50M | $27.71M | $17.56M | ||||||||||||
| Americas | — | $13.73M | $21.28M | $43.54M | ||||||||||||
| United States | $17.00M | — | — | — | ||||||||||||
| Emea | $56.54M | $22.91M | $10.36M | $9.29M | ||||||||||||
| Europe | — | — | — | — | ||||||||||||
| United Kingdom | — | — | — | — | ||||||||||||
| Rest Of World | — | — | — | — | ||||||||||||
| India | — | — | — | — | ||||||||||||
| Singapore | — | — | — | — | ||||||||||||
| Switzerland | — | — | — | — | ||||||||||||
| Other Asian Countries | — | — | — | — | ||||||||||||
| Others | — | — | — | — | ||||||||||||
| Total | $138.59M | $70.14M | $59.35M | $70.39M |
Codexis brought in $70.39M from its three regions in fiscal 2025, the year ended December 31, 2025. That was up 18.6% from $59.35M in fiscal 2024. Americas was the largest at $43.54M (61.9%), ahead of Apac at $17.56M (24.9%) and Emea at $9.29M (13.2%).
Compared with fiscal 2024, Americas grew fastest, up 104.6% to $43.54M, while Apac fell the most, down 36.6% to $17.56M.
Codexis stopped reporting United States as a separate region after fiscal 2022, when it brought in $17.00M.
Research & Development Revenue was Codexis’s largest product and service line in fiscal 2025, bringing in $44.36M of $70.39M (63%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue | $116.68M | $42.91M | $36.79M | $26.03M | ||||||
| Research & Development Revenues | — | — | — | — | ||||||
| Research & Development Revenue | $21.91M | $27.24M | $22.56M | $44.36M | ||||||
| Product Sales | — | — | — | — | ||||||
| Total | $138.59M | $70.14M | $59.35M | $70.39M |
Codexis brought in $70.39M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 18.6% from $59.35M in fiscal 2024. Research & Development Revenue was the largest at $44.36M (63.0%), ahead of Product Revenue at $26.03M (37.0%).
Compared with fiscal 2024, Research & Development Revenue grew 96.6% to $44.36M, while Product Revenue fell 29.2% to $26.03M. From fiscal 2022 to 2025, combined revenue from these lines fell from $138.59M to $70.39M, a compound annual decline of 20.2%. Research & Development Revenue's share of the total rose from 15.8% to 63.0%.
Performance Enzymes was Codexis’s largest segment in fiscal 2020, bringing in $48.11M of $69.06M (70%).
| Segment | FY 2017 | FY 2018 | FY 2019 | FY 2020 |
|---|---|---|---|---|
| Performance Enzymes | $42.33M | $47.07M | $58.16M | $48.11M |
| Novel Biotherapeutics | $7.69M | $13.52M | $10.30M | $20.95M |
| Total | $50.02M | $60.59M | $68.46M | $69.06M |
Codexis brought in $69.06M from its two segments in fiscal 2020, the year ended December 31, 2020. That was up 0.9% from $68.46M in fiscal 2019. Performance Enzymes was the largest at $48.11M (69.7%), ahead of Novel Biotherapeutics at $20.95M (30.3%).
Compared with fiscal 2019, Novel Biotherapeutics grew 103.4% to $20.95M, while Performance Enzymes fell 17.3% to $48.11M. From fiscal 2017 to 2020, combined revenue from these segments grew from $50.02M to $69.06M, a compound annual growth rate of 11.3%. Performance Enzymes' share of the total fell from 84.6% to 69.7%.
Codexis (CDXS) reports its revenue by geography, by product and service and by segment. In fiscal 2025, Americas was its largest region, bringing in $43.54M (61.9% of the total), followed by Apac at $17.56M (24.9%).
Americas was Codexis' largest region in fiscal 2025, bringing in $43.54M, or 61.9% of the $70.39M total across its three regions.
Research & Development Revenue was Codexis' largest product and service line in fiscal 2025, bringing in $44.36M, or 63.0% of the $70.39M total across its two product and service lines.
Performance Enzymes was Codexis' largest segment in fiscal 2020, bringing in $48.11M, or 69.7% of the $69.06M total across its two segments.
Among Codexis' regions that make up at least 2% of revenue, Americas grew fastest in fiscal 2025, up 104.6% from $21.28M to $43.54M.
Every figure comes from Codexis' annual financial filings, as reported. Each line keeps the name Codexis gives it, and years follow its fiscal calendar.
Codexis' revenue by geography goes back to fiscal 2010, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.